BEGIN:VCALENDAR PRODID:-//eluceo/ical//2.0/EN VERSION:2.0 CALSCALE:GREGORIAN BEGIN:VEVENT UID:f44377ef878f8e5bf6635cbadbd699ae DTSTAMP:20240718T052545Z SUMMARY:Recent advances in in vivo flow cytometry DESCRIPTION:The sensitivity of conventional flow cyt ometry is limited by t he small volume of blood collected\, in which no less than one disease-spe cific markers can be detected. It leads to missing many thousands of abnor mal cells in the whole blood volume (~5 L in adults)\, which can be suffic ient for disease progression to barely treatable or incurable stage. For e xample\, despite enormous efforts to detect circulating tumor cells (CTCs) responsible for 90% of all cancer deaths as a result of the development o f deadly metastases\, the mortality rates for metastatic cancer have still been almost flat. To solve this problem we introduced in vivo flow cytome try for detection of rare circulating biomarkers directly in the bloodstre am using blood vessels as natural tubes with native cell flow. In this tec hnology\, laser irradiates vessels of interests followed by the detection of photoacoustic (PA) waves from circulating objects using ultrasound tran sducer attached to the skin. The PA waves are generated either using intri nsic contrast agents (e.g.\, melanin) or absorbing low toxic plasmonic nan oprobes functionalized to specific markers. In this report we summarize re cent advances of new generation of in vivo multicolor flow cytometry platf orm using multispectral lasers\, fiber-based transducers\, label-free and/ or multiplex molecular targeting\, plasmonic probes with ultrasharp PA spe ctral resonances\, in vivo magnetic capturing of CTCs\, and combination of PA diagnosis with photothermal (PT) elimination of abnormal cells. The ca pacity of this new technology was first demonstrated in preclinical models for real-time detection of bulk and stem CTCs\, S. aureus\, and sickle ce lls. Then\, the clinical prototype of in vivo PA flow cytometry (PAFC) pro vided the assessment of ~1 L of patient blood during 30-60 minutes. The fi rst clinical studies focused on detection of CTCs and cancer-associated cl ots in melanoma patients. The PAFC data in vivo were validated in vitro wi th conventional flow cytometry\, immunohistochemical staining\, and magnet ic kits. The obtained results demonstrate that PAFC is more sensitivity ( ≥100-fold) \, accurate and rapid (≤ 1 hour) that conventional techniqu e. Unlike typical blood sampling involving extraction of a volume of blood ranging from 10 μL (drop) to a few mL (CTC assays)\, in vivo examination involves nearly the entire volume of blood passing through 1–2-mm-diame ter peripheral vessels over 0.5–1 h and thus will enable a dramatic incr ease in diagnostic sensitivity\, ultimately up to 103–105 times\, reflec ting the ratio of the volume of blood sampled in vivo to that in vitro. Ac cording to pilot clinical results\, the portable personal flow cytometer c an provide a breakthrough in early diagnosis of cancer\, infection and car diovascular disorders with a potential to inhibit\, if not prevent\, metas tasis\, sepsis\, and strokes or heart attack through the use of well-timed personalized therapy. URL: DTSTART:20151006T150000 DTEND:20151006T150000 LOCATION:IPHT boardroom END:VEVENT BEGIN:VTIMEZONE TZID:Europe/Berlin BEGIN:DAYLIGHT DTSTART:20151006T150000 TZNAME:CEST TZOFFSETTO:+0200 TZOFFSETFROM:+0200 END:DAYLIGHT END:VTIMEZONE END:VCALENDAR